A Phase 1 interventional study of Uprifosbuvir and Ruzasvir in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-17.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Hepatitis C, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Merck & Co., Inc.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 63rd largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2016, is one of 12 in phase 1, and was the 109th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc is open now. The open studies under Hepatitis C, Chronic, anywhere →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 23 · Phase 3 34 · Phase 4 8
First in 2002; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 113 across the 72 interventional studies, 442 across the 35 observational. Of the 106 that completed or were terminated, 81 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a non-randomized, open-label, single-dose study to evaluate the pharmacokinetics (PK) of uprifosbuvir (MK-3682), the M5 and M6 metabolites of uprifosbuvir, and ruzasvir (MK-8408), in participants with moderate hepatic insufficiency (HI), participants with severe HI, and age-matched healthy control participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
HI Participants Only:
All Participants:
Exclusion Criteria:
HI Participants Only:
Healthy Participants Only:
All Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
Drug: Uprifosbuvir · Drug: Ruzasvir
On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
Drug: Uprifosbuvir · Drug: Ruzasvir
On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
Drug: Uprifosbuvir · Drug: Ruzasvir
A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
Also known as: MK-3682
A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
Also known as: MK-8408
Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity (AUC0-inf) of Uprifosbuvir
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Area Under the Plasma Drug Concentration-Time Curve From Start of Dosing to 24 Hours Post-Dose (AUC0-24hr) of Uprifosbuvir
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Maximum Plasma Drug Concentration (Cmax) of Uprifosbuvir
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Plasma Drug Concentration at 24 Hours (C24hr) of Uprifosbuvir
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: 24 hours post-dose
Time to Reach Cmax (Tmax) of Uprifosbuvir
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Apparent Terminal Half-Life (t1/2) of Uprifosbuvir
t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Apparent Total Clearance From Plasma After Oral Administration (CL/F) of Uprifosbuvir
CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of Uprifosbuvir
Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-last of Uprifosbuvir Metabolite M5
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-inf of Uprifosbuvir Metabolite M5
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-24hr of Uprifosbuvir Metabolite M5
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Cmax of Uprifosbuvir Metabolite M5
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
C24hr of Uprifosbuvir Metabolite M5
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: 24 hours post-dose
Lag Time (Tlag) for Uprifosbuvir Metabolite M5
Tlag is a measure of the time delay between drug administration and the onset of absorption, where onset of absorption is defined as "the time point prior to the first observed/measured non-zero plasma concentration". The Tlag of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm (in this study Tlag was only calculated for the M5 uprifosbuvir metabolite).
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Tmax of Uprifosbuvir Metabolite M5
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Apparent t1/2 of Uprifosbuvir Metabolite M5
Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-last of Uprifosbuvir Metabolite M6
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-inf of Uprifosbuvir Metabolite M6
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-24hr of Uprifosbuvir Metabolite M6
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Cmax of Uprifosbuvir Metabolite M6
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
C24hr of Uprifosbuvir Metabolite M6
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: 24 hours post-dose
Tmax of Uprifosbuvir Metabolite M6
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Apparent t1/2 of Uprifosbuvir Metabolite M6
Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-last of Ruzasvir
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-inf of Ruzasvir
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
AUC0-24hr of Ruzasvir
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose
Maximum Plasma Drug Concentration (Cmax) of Ruzasvir
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
C24hr of Ruzasvir
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: 24 hours post-dose
Tmax of Ruzasvir
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0), and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Apparent t1/2 of Ruzasvir
Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
CL/F of Ruzasvir
CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Vz/F of Ruzasvir
Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
Time frame: Pre-dose (0) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 14, 16, 18, 20, 24, 48, 72, 96, and 120 hours post-dose
Participants with moderate hepatic insufficiency (HI), severe HI, and healthy controls were recruited at 2 study centers in the United States.
| Milestone | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir | 5.34 (3.55 to 8.05) | 8.02 (5.32 to 12.1) | 3.74 (2.48 to 5.63) |
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Infinity (AUC0-inf) of Uprifosbuvir | 5.39 (3.57 to 8.12) | 8.09 (5.37 to 12.2) | 3.76 (2.50 to 5.68) |
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Area Under the Plasma Drug Concentration-Time Curve From Start of Dosing to 24 Hours Post-Dose (AUC0-24hr) of Uprifosbuvir | 5.35 (3.55 to 8.05) | 8.02 (5.33 to 12.1) | 3.74 (2.48 to 5.63) |
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Maximum Plasma Drug Concentration (Cmax) of Uprifosbuvir | 1560 (1030 to 2360) | 2130 (1410 to 3240) | 1180 (778 to 1790) |
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Plasma Drug Concentration at 24 Hours (C24hr) of Uprifosbuvir | 7.01 (0.00 to 26.9) | 8.56 (0.00 to 85.5) | 2.55 (0.00 to 22.3) |
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Time to Reach Cmax (Tmax) of Uprifosbuvir | 1.00 (0.50 to 4.00) | 0.50 (0.50 to 1.50) | 1.25 (0.50 to 3.00) |
t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Apparent Terminal Half-Life (t1/2) of Uprifosbuvir | 3.66 ± 21.7 | 3.56 ± 47.5 | 3.17 ± 38.5 |
CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| L/hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Apparent Total Clearance From Plasma After Oral Administration (CL/F) of Uprifosbuvir | 153 ± 39.9 | 102 ± 61.1 | 219 ± 77.6 |
Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| L | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) of Uprifosbuvir | 809 ± 43.8 | 524 ± 57.0 | 1000 ± 83.0 |
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-last of Uprifosbuvir Metabolite M5 | 6.46 (4.90 to 8.52) | 6.79 (5.15 to 8.95) | 8.11 (6.15 to 10.7) |
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-inf of Uprifosbuvir Metabolite M5 | 6.78 (5.15 to 8.93) | 7.22 (5.48 to 9.50) | 8.44 (6.41 to 11.1) |
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-24hr of Uprifosbuvir Metabolite M5 | 2.41 (1.85 to 3.13) | 2.28 (1.75 to 2.96) | 3.12 (2.40 to 4.05) |
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Cmax of Uprifosbuvir Metabolite M5 | 169 (130 to 220) | 151 (117 to 197) | 203 (156 to 264) |
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| C24hr of Uprifosbuvir Metabolite M5 | 124 (93.9 to 164) | 122 (92.8 to 162) | 150 (114 to 198) |
Tlag is a measure of the time delay between drug administration and the onset of absorption, where onset of absorption is defined as "the time point prior to the first observed/measured non-zero plasma concentration". The Tlag of the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm (in this study Tlag was only calculated for the M5 uprifosbuvir metabolite).
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Lag Time (Tlag) for Uprifosbuvir Metabolite M5 | 3.00 (2.00 to 3.00) | 2.53 (2.00 to 3.00) | 2.00 (1.50 to 3.02) |
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Tmax of Uprifosbuvir Metabolite M5 | 14.00 (12.00 to 18.00) | 16.00 (12.00 to 20.00) | 15.00 (10.00 to 16.00) |
Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M5 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Apparent t1/2 of Uprifosbuvir Metabolite M5 | 24.09 ± 17.2 | 25.64 ± 19.2 | 23.59 ± 9.7 |
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-last of Uprifosbuvir Metabolite M6 | 28.6 (22.6 to 36.1) | 27.4 (21.6 to 34.6) | 41.8 (33.0 to 52.9) |
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-inf of Uprifosbuvir Metabolite M6 | 30.1 (23.5 to 38.6) | 28.7 (22.4 to 36.7) | 47.0 (36.7 to 60.2) |
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-24hr of Uprifosbuvir Metabolite M6 | 13.1 (10.6 to 16.1) | 13.2 (10.8 to 16.3) | 16.6 (13.5 to 20.4) |
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Cmax of Uprifosbuvir Metabolite M6 | 851 (675 to 1070) | 834 (662 to 1050) | 1070 (846 to 1340) |
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| C24hr of Uprifosbuvir Metabolite M6 | 402 (332 to 487) | 410 (339 to 497) | 564 (465 to 683) |
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Tmax of Uprifosbuvir Metabolite M6 | 6.00 (2.00 to 12.00) | 4.00 (3.00 to 8.00) | 4.00 (3.00 to 6.00) |
Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for the M6 metabolite of uprifosbuvir 450 mg (given in combination with ruzasvir 60 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Apparent t1/2 of Uprifosbuvir Metabolite M6 | 26.96 ± 19.4 | 26.45 ± 31.3 | 33.98 ± 37.7 |
AUC0-last is a measure of the mean plasma drug concentration from time of dosing to the last quantifiable sample. The AUC0-last for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-last of Ruzasvir | 2.30 (1.75 to 3.02) | 2.70 (2.07 to 3.51) | 1.98 (1.52 to 2.58) |
AUC0-inf is a measure of the mean plasma drug concentration from time of dosing to infinity. The AUC0-inf for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-inf of Ruzasvir | 2.60 (1.99 to 3.41) | 3.32 (2.56 to 4.31) | 2.10 (1.62 to 2.73) |
AUC0-24hr is a measure of the mean plasma drug concentration from time of dosing to 24 hours post-dose. The AUC0-24hr for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| µM*hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| AUC0-24hr of Ruzasvir | 1.04 (0.729 to 1.49) | 1.05 (0.744 to 1.48) | 1.17 (0.830 to 1.65) |
Cmax is the maximum observed plasma drug concentration after dosing. The Cmax for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Maximum Plasma Drug Concentration (Cmax) of Ruzasvir | 105 (65.6 to 167) | 92.5 (58.9 to 145) | 137 (87.0 to 215) |
C24hr is a measure of plasma drug concentration 24 hours after dosing. The C24hr of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| nM | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| C24hr of Ruzasvir | 27.6 (21.4 to 35.7) | 32.4 (25.2 to 41.5) | 23.0 (18.0 to 29.5) |
Tmax is the time required to reach maximum plasma drug concentration (i.e., Cmax). The Tmax of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Tmax of Ruzasvir | 3.00 (1.50 to 24.00) | 2.03 (1.50 to 4.00) | 3.00 (2.00 to 4.00) |
Apparent t1/2 is a measure of how long it takes to clear 50% of drug after reaching Cmax. The t1/2 for ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Apparent t1/2 of Ruzasvir | 38.08 ± 23.1 | 47.26 ± 36.6 | 30.43 ± 14.6 |
CL/F is a measure of the apparent rate at which drug is removed from the body via renal, hepatic, and other clearance pathways after oral administration. The CL/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| L/hr | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| CL/F of Ruzasvir | 28.4 ± 36.7 | 20.6 ± 52.8 | 32.6 ± 54.6 |
Vz/F is the apparent volume of distribution during the terminal phase after non-intravenous administration. The Vz/F of ruzasvir 60 mg (given in combination with uprifosbuvir 450 mg) was calculated for each arm.
| L | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Vz/F of Ruzasvir | 1560 ± 49.8 | 1400 ± 37.9 | 1430 ± 48.1 |
Collected over Up to 14 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moderate HI Participants | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Severe HI Participants | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Healthy Participants | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | Moderate HI Participants | Severe HI Participants | Healthy Participants |
|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 0/8 | 1/8 | 0/8 |
| FlatulenceGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| DizzinessNervous system disorders | 0/8 | 1/8 | 0/8 |
| Hepatic encephalopathyNervous system disorders | 0/8 | 1/8 | 0/8 |
| HeadacheNervous system disorders | 0/8 | 1/8 | 0/8 |
| Age, Continuous(Years) | Moderate HI Participants | Severe HI Participants | Healthy Participants | Total |
|---|---|---|---|---|
| Mean | 58.3 ± 8.7 | 55.4 ± 8.2 | 57.6 ± 6.3 | 57.1 ± 7.5 |
| Sex: Female, Male(Participants) | Moderate HI Participants | Severe HI Participants | Healthy Participants | Total |
|---|---|---|---|---|
| Female | 2 | 3 | 3 | 8 |
| Male | 6 | 5 | 5 | 16 |
No study locations are listed for this record.
Ran from Jan 2016 to primary completion in Jan 2017, 11 months.
Results were first posted in Sep 2018, 1 year 8 months after primary completion.
Of 21 phase 1 interventional studies under Hepatitis C, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 11 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Uprifosbuvir · Ruzasvir